Effect of Shenfu Injection on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial
单位:[1]Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China,首都医科大学附属安贞医院[2]Department of Radiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China,首都医科大学附属安贞医院[3]Department of Radiology, Beijing Friendship Hospital, Capital Medical University, Beijing, China,医技科室影像中心放射科首都医科大学附属北京友谊医院[4]Department of Emergency Medicine, Thomas Jefferson University, Philadelphia, PA, United States
Background: Shenfu injection is a traditional Chinese medicine formulation that alleviates ischemia-reperfusion injury through multiple pharmacologic effects. However, no data are available regarding its efficacy in patients with myocardial infarction. We aimed to examine the effects of Shenfu injection on infarct size in patients with ST segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).<br>Methods: From April 2016 to February 2018, 40 patients with first-time anterior STEMI undergoing primary PCI within 6 h of symptom onset were randomized 1:1 to intravenous Shenfu injection (80 ml Shenfu injection + 70 ml 5% glucose injection) or placebo (150 ml 5% glucose injection) before reperfusion. Treatment started before PCI and maintained for 5 days after PCI. The primary end point was infarct size assessed by CK-MB area under the curve (AUC) over 72 h and cardiac magnetic resonance (CMR) imaging 4 & PLUSMN; 1 days after PCI.<br>Results: Infarct size by area under the curve for CK-MB over 72 h did not differ between the Shenfu injection and placebo groups (5602.5 [3539.4-7526.4] vs. 6403.2 [2234.4-8340.6] ng & BULL;h/ml, P = 0.82). Among 32 patients who underwent CMR Imaging, a nominal reduction in infarct size was observed in the Shenfu injection group compared with the placebo group (23.9 [15.2-28.5] % vs. 27 [21.9-31.9] %, P = 0.42). After excluding patients with no or minimal infarct, there was a trend toward reduction in infarct size in the Shenfu injection group (24.1 [20.3-29.3] % vs. 29.1 [24.5-32] %, P = 0.18). Incidence of adverse events was similar between the groups.<br>Conclusions: This pilot study showed that the use of Shenfu injection was safe but did not reduce infarct size by CMR Imaging and CK-MB release kinetics in reperfused patients with STEMI. Larger studies (confining to patients with extensive infarct size) to evaluate the efficacy of Shenfu injection on reperfusion injury are warranted.Clinical Trail Registration: , identifier: NCT02709798.
基金:
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81870322]; Beijing Municipal Administration of Hospitals' Ascent Plan [DFL20180601]; Natural Science Foundation of Beijing, ChinaBeijing Natural Science Foundation [7191002]; Beijing Nova ProgramBeijing Municipal Science & Technology Commission [Z201100006820087]; Fund for Beijing Science & Technology Development of TCM [QN2018-01]; Beijing Municipal Administration of Hospitals Incubating Program [PZ2019005]
第一作者单位:[1]Center for Coronary Artery Disease, Beijing Anzhen Hospital, Capital Medical University, Beijing, China,
通讯作者:
推荐引用方式(GB/T 7714):
Wang Xiao,Miao Huangtai,Yan Yan,et al.Effect of Shenfu Injection on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial[J].FRONTIERS in CARDIOVASCULAR MEDICINE.2021,8:doi:10.3389/fcvm.2021.736526.
APA:
Wang, Xiao,Miao, Huangtai,Yan, Yan,Guo, Ruifeng,Gong, Wei...&Nie, Shaoping.(2021).Effect of Shenfu Injection on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial.FRONTIERS in CARDIOVASCULAR MEDICINE,8,
MLA:
Wang, Xiao,et al."Effect of Shenfu Injection on Reperfusion Injury in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Segment Elevation Myocardial Infarction: A Pilot Randomized Clinical Trial".FRONTIERS in CARDIOVASCULAR MEDICINE 8.(2021)